Corrections

Author Correction: Molecular subtypes of difuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas Kamburov, Robert A. Redd, Mike S. Lawrence, Margaretha G. M. Roemer, Amy J. Li, Marita Ziepert, Annette M. Staiger , Jeremiah A. Wala , Matthew D. Ducar, Ignaty Leshchiner , Ester Rheinbay, Amaro Taylor-Weiner, Caroline A. Coughlin, Julian M. Hess, Chandra S. Pedamallu, Dimitri Livitz , Daniel Rosebrock, Mara Rosenberg, Adam A. Tracy, Heike Horn, Paul van Hummelen, Andrew L. Feldman , Brian K. Link, Anne J. Novak, James R. Cerhan, Thomas M. Habermann, Reiner Siebert, Andreas Rosenwald, Aaron R. Thorner, Matthew L. Meyerson , Todd R. Golub , Rameen Beroukhim, Gerald G. Wulf, German Ott, Scott J. Rodig, Stefano Monti, Donna S. Neuberg , Markus Loefer, Michael Pfreundschuh, Lorenz Trümper, Gad Getz and Margaret A. Shipp

Correction to: Nature Medicine https://doi.org/10.1038/s41591-018-0016-8, published online 30 April 2018. In the version of this article originally published, an asterisk was omitted from Fig. 1a. The asterisk has been added to the figure. Additionally, a “NOTCH2” label was erroneously included in Fig. 4a. The label has been removed. The errors have been corrected in the PDF and HTML versions of this article.

Original a Corrected a * 100 Syn. Frame shift

80 197 100 Syn. Missense In frame indel Frame shift Syn.

19 7 60 80 Missense In frame indel Splice site Other non syn. Syn. Non syn. Mb 40 60 Splice site Other non syn. Nonsense Non syn. Mb 40 Nonsense 20 20 Mutations per 0

Mutations pe r 0 21% TP53 18% MYD88 21% TP53 17% CREBBP 18% MYD88 14% CD79B 17% CREBBP 12% HLA−B 14% CD79B 9% CD70 12% HLA−B 8% FAS 9% CD70 9% KLHL6 8% FAS 7% 9% KLHL6 PRDM1 7% PRDM1 7% TBL1XR1 7% TBL1XR1 14% BTG1 14% BTG1 218 17% BCL2 218 17% BCL2 11% CARD11 11% CARD11 8% HLA−A 8% HLA−A 225 22% PIM1 225 22% PIM1 5% CCND3 5% CCND3 9% B2M 9% B2M 14% TNFRSF14 14% TNFRSF14 12% HIST1H1C 12% HIST1H1C 6% TMEM30A 6% TMEM30A 12% TMSB4X 12% TMSB4X 11% EBF1 11% EBF1 6% CD58 6% CD58 9% TNFAIP3 9% TNFAIP3 25% KMT2D 25% KMT2D 7% MEF2B 7% MEF2B 5% NFKBIA 5% NFKBIA 4% HLA−C 4% HLA−C 5% RHOA 5% RHOA 6% EEF1A1 6% EEF1A1 4% UBE2A 4% UBE2A 7% EZH2 7% EZH2 4% POU2AF1 4% POU2AF1 13% HIST1H1E 13% HIST1H1E 6% POU2F2 6% POU2F2 6% BRAF 6% BRAF 14% SGK1 14% SGK1 10% IGLL5 10% IGLL5 6% STAT3 6% STAT3 11% GNA13 11% GNA13 6% BCL6 6% BCL6 11% ACTB 11% ACTB 5% STAT6 5% STAT6 4% LYN 4% LYN 3% HVCN1 3% HVCN1 7% ETV6 7% ETV6 7% NOTCH2 7% NOTCH2 3% CXCR4 3% CXCR4 3% KRAS 3% KRAS 3% IKZF3 3% IKZF3 4% TOX 4% TOX 9% HIST1H1B 9% HIST1H1B 6% HIST1H2BC 6% HIST1H2BC 2% CRIP1 2% CRIP1 6% HIST1H2AC 6% HIST1H2AC 4% PTPN6 4% PTPN6 5% BCL10 5% BCL10 6% CD83 6% CD83 3% PTEN 3% PTEN 8% EP300 8% EP300 3% GRB2 3% GRB2 3% NFKBIE 3% NFKBIE 8% HIST1H2BK 8% HIST1H2BK 3% ZC3H12A 3% ZC3H12A 2% XPO1 2% XPO1 8% IRF8 8% IRF8 9% SPEN 9% SPEN 3% CD274 3% CD274 7% HIST1H1D 7% HIST1H1D 8% ZFP36L1 8% ZFP36L1 2% RAD9A 2% RAD9A 12% DTX1 12% DTX1 3% YY1 3% YY1 2% NAV1 2% NAV1 1% CCL4 1% CCL4 6% HIST1H2AM 6% HIST1H2AM 7% LTB 7% LTB 3% SMEK1 3% SMEK1 2% NANOG 2% NANOG 2% HLA−DMA 2% HLA−DMA 4% SIN3A 4% SIN3A 5% ETS1 5% ETS1 4% PRKCB 4% PRKCB 1% PRPS1 1% PRPS1 8% PDE4DIP 8% PDE4DIP 3% TLR2 3% TLR2 2% ZNF423 2% ZNF423 3% SF3B1 3% SF3B1 3% CIITA 3% CIITA 3% NLRP8 3% NLRP8 3% BCL11A 3% BCL11A 4% ZEB2 4% ZEB2 3% GNAI2 3% GNAI2 1% FUT5 1% FUT5 3% HIST1H3B 3% HIST1H3B 5% HIST2H2BE 5% HIST2H2BE 1% COQ7 1% COQ7 2% IL6 2% IL6 100 100 200100 0 0.52.0 200 100 0 80 0.52.0 80 Number of 60 –log10 Number of 60 –log10 40 (q value) mutations 40 (q value) mutations Allelic Allelic fraction 20 20 fractio n 0 0

Fig. 1a | Original and corrected.

1290 Nature Medicine | VOL 24 | AUGUST 2018 | 1290–1292 | www.nature.com/naturemedicine Nature Medicine Corrections

Original a Amplifications Deletions Arm-level Focal 1q23.3 (9%,549|15; FCGR2B),NOTCH2, Arm-level Focal 1p36.32 (24%,95|1;TNFRSF14), TNFRSF14 HIST2H2BE,PDE4DIP, MCL1 1p36.11 (16%,50|1;-) 1 1p31.1 (15%,10|-;-) 1q (21%|1104|23) 1q32.1 (9%,208|5;CDC73), NAV1 1 1p13.1 (14%,43|4;NRAS,TRIM33,FAM46C), CD58 1q42.12 (8%,262|2;-) 2 2p16.1 (27%,4|1;REL) 2 2q22.2 (10%,9|-;-), ZEB2 3p (17%|586|18) 3 3p21.31 (20%,81|2;RHOA,NCKIPSD), RHOA 3 3q (24%,685|20) 3q28 (5%,11|2;-), BCL6* 3q28 (8%,95|3;LPP), BCL6*, TP63 4 4 4q21.22 (16%,109|1;-) 5p (16%,185|3) 4q35.1 (15%,180|1;-), TLR2 5 5q (14%,837|18) 5 6p21.33 (12%,2|-;-) 6p21.1(5%,79|2;CCND3,TFEB), 6p (18%,492|12) 6 CCND3 6q14.1(13%,8|-;-),TMEM30A 6q (20%,508|15;-) 6 6q14.3(15%,40|-;-) 7p (32%,374|11) 7 7q22.1 (5%,156|2;CUX1,TRRAP) 6q21(19%,67|2;FOXO3,PRDM1), PRDM1 7q (29%,731|19) 7 8 8q24.22 (21%,3|-;-) 6q23.3(16%,7|1;-),TNFAIP3 8 8p12.1 (12%,9|-;-),TOX 9 9p24.1 (15%,17|3;PD-L1,PD-L2,JAK2), 9q (13%,685|19) 9p21.3 (15%,37|2/21;MLLT3), CDKN2A PD-L1*,PD-L2 9 10 9q21.13 (12%,245|7;-) 11p (17%,510|11) 10 10q23.31 (12%,31|2;FAS), FAS, PTEN 11 11q23.3 (10%,8|-;-) 11q (19%,929|22) 11 12p12.1 (9%,7|-;-) 12 12p13.2 (12%,46|2;CDKN1B), ETV6* 12 13 13q14.2 (14%,41|1;RB1) 12q (19%,840|28) 13q31.3 (9%,134|1;-), miR-17~92 13 14 13q34 (13%,84|1;ERCC5) 14 15 14q32.31 (13%,10|-;-) 13q (13%,449|8) 17p (22%,394|10) 15 15q15.3 (23%,91|1;-), B2M 16 17q24.3 (16%,6|-;-) TP53 16q12.1 (12%,137|2;CYLD),ZNF423 18p (23%,90|-) 17 16 17 17p11.2 (4%,31|1;-) 18q (32%,251|7) 18 17q25.1 (7%,15|-;-), GRB2 18q21.33 (7%,103|3;BCL2,MALT1,KDSR), BCL2* 18 19q (14%,950|15) 19 18q23 (13%,15|-;-) 20 19q13.42 (10%,203|3;TFPT),NLRP8 21 20 19p13.2 (9%,6|-;-) 21q (16%,288|5;-) 22 21 19p13.3 (14%,23|-;-),CD70 10 5 0510 22 19p13.32 (5%,10|-;-) 10 5 0510 -log10 (q-value) -log10 (q-value)

Corrected

Amplifications Deletions a Arm-level Focal 1p36.32 (24%,95 1;TNFRSF14), TNFRSF14 1q23.3 (9%,549∣15; FCGR2B), Arm-level Focal ∣ HIST2H2BE,PDE4DIP, MCL1 1p36.11 (16%,50∣1;–) 1 1p31.1 (15%,10∣–;–) 1q (21%∣1104∣23) 1q32.1 (9%,208|5;CDC73), NAV1 1 1p13.1 (14%,43∣4;NRAS,TRIM33,FAM46C), CD58 1q42.12 (8%,262∣2;–) 2 2p16.1 (27%,4∣1;REL) 2 2q22.2 (10%,9∣–;–), ZEB2 3p (17% 586 18) ∣ ∣ 3 3p21.31 (20%,81 2;RHOA,NCKIPSD), RHOA 3 ∣ 3q (24%,685∣20) 3q28 (5%,11∣2;–), BCL6* 3q28 (8%,95∣3;LPP), BCL6*, TP63 4 4 4q21.22 (16%,109∣1;–) 5p (16%,185∣3) 4q35.1 (15%,180∣1;–), TLR2 5 5q (14%,837∣18) 5 6p21.33 (12%,2∣–;–) 6p21.1(5%,79∣2;CCND3,TFEB), 6q14.1(13%,8∣–;–),TMEM30A 6p (18%,492∣12) 6 CCND3 6 7p (32%,374∣11) 6q (20%,508|15;-) 6q14.3(15%,40∣–;–) 7 7q22.1 (5%,156 2;CUX1,TRRAP) 6q21(19%,67|2;FOXO3,PRDM1), PRDM1 7q (29%,731 19) ∣ 7 ∣ 6q23.3(16%,7 1;–),TNFAIP3 8 8q24.22 (21%,3∣–;–) ∣ 8 8p12.1 (12%,9∣–;–),TOX 9 9p24.1 (15%,17∣3;PD-L1,PD-L2,JAK2), 9p21.3 (15%,37∣2/21;MLLT3), CDKN2A 9q (13%,685∣19) 9 PD-L1*,PD-L2 9q21.13 (12%,245 7;–) 10 ∣ 10 11p (17%,510 11) 11q23.3 (10%,8 –;–) 10q23.31 (12%,31∣2;FAS), FAS, PTEN ∣ 11 ∣ 11 11q (19%,929∣22) 12p12.1 (9%,7∣–;–) 12 12p13.2 (12%,46∣2;CDKN1B), ETV6* 12 13 13q14.2 (14%,41∣1;RB1) 12q (19%,840|28) 13q31.3 (9%,134∣1;–), miR-17~92 13 14 13q34 (13%,84∣1;ERCC5) 14 15 17p (22%,394|10) 14q32.31 (13%,10∣–;–) 13q (13%,449∣8) 15 15q15.3 (23%,91∣1;–), B2M 16 TP53 18p (23%,90 –) 17q24.3 (16%,6∣–;–) 16 16q12.1 (12%,137∣2;CYLD), ZNF423 ∣ 17 17 17p11.2 (4%,31∣1;–) 18q (32%,251∣7) 18 17q25.1 (7%,15 –;–), GRB2 18q21.33 (7%,103∣3;BCL2,MALT1,KDSR), BCL2* 18 ∣ 19q (14%,950 15) 19 18q23 (13%,15∣–;–) ∣ 20 19q13.42 (10%,203∣3;TFPT),NLRP8 21 20 19p13.2 (9%,6∣–;–) 21q (16%,288∣5;–) 22 21 19p13.3 (14%,23 –;–),CD70 22 ∣ 10 5 0510 19p13.32 (5%,10∣–;–) 10 5 0510 –log10 (q value) –log10 (q value)

Fig. 4a | Original and corrected.

Published online: 28 June 2018 https://doi.org/10.1038/s41591-018-0097-4

Nature Medicine | VOL 24 | AUGUST 2018 | 1290–1292 | www.nature.com/naturemedicine 1291